drug development

The firm now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.

The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.

The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies. 

Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.

Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.

Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.